Clinical trial
An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With…
NCT00132925 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00132925 |
|---|---|
| Title | An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis |
| Official title | An Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD Children Ages 2-5 Years With Perennial Allergic Rhinitis |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rhinitis, Allergic, Perennial |
| Intervention type | Drug |
| Interventions | Triamcinolone |
| Enrollment | 460 |
| Start date | Nov 1, 2003 |
| Completion | Feb 1, 2006 |
| First posted | Aug 22, 2005 |
| Last update posted | Jan 11, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: